drugset / Trial / NCT04182516
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.
Timeline
- Start
- 2019-11-25
- Primary completion
- 2023-03-31
- Completion
- 2024-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NMS-03305293 | Unknown | — | Oral |
Indications
No indication recorded.